Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
11.33
-0.26 (-2.24%)
At close: Apr 28, 2026, 4:00 PM EDT
11.33
0.00 (0.00%)
After-hours: Apr 28, 2026, 5:16 PM EDT
Company Description
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 371 |
| CEO | Steven Basta |
Contact Details
Address: 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 United States | |
| Phone | 877 742 8466 |
| Website | phathompharma.com |
Stock Details
| Ticker Symbol | PHAT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001783183 |
| CUSIP Number | 71722W107 |
| ISIN Number | US71722W1071 |
| Employer ID | 82-4151574 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven L. Basta M.B.A. | Chief Executive Officer, President and Director |
| David A. Socks | Co-Founder |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder |
| Sanjeev Narula | Chief Financial and Business Officer |
| Anne Marie Cook Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Jonathan Bentley | Senior Vice President and Head of Sales, Operations and Training |
| Robert Breedlove | Vice President of Finance and Principal Accounting Officer |
| Eric Sciorilli | Director of Business Development and Investor Relations |
| Bill Aprea J.D. | Senior Vice President, Chief Compliance Officer and Deputy Chief Legal Officer |
| Nancy R. Phelan | Senior Vice President of Marketing and Analytics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 7, 2026 | ARS | Filing |
| Apr 7, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2026 | SCHEDULE 13G | Filing |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Jan 27, 2026 | SCHEDULE 13G/A | Filing |
| Jan 8, 2026 | 8-K | Current Report |
| Jan 8, 2026 | 424B5 | Filing |